Biotech Basics: How to Spot When Financing Is Coming
Education - Bio investing is driven by near-term catalysts, rather than a buy & hold strategy. There is a 7.9% likelihood of FDA approval from Phase 1, … Continue Reading
Read nowAuthor Archives: Editorial Staff
ADCs Back in Cancer Spotlight
Research - In mid-March 2023, Pfizer acquired Seagen (SGEN) for $43B, making it the largest biopharma transaction in three years. Seagen, considered the leader in antibody-drug conjugate … Continue Reading
Read now
A Very Early Indicator That Bio Markets Could Be Nearing Inflection
Insights - There are early signs that private money in biotech is being accumulated but sitting on the sidelines waiting to be deployed. Q1 2023 was the … Continue Reading
Read now
Day One (DAWN) Sliding On Concerns of Competitoin and Trial Changes
Insights - In mid-March, Novartis’ combination Tafinlar (dabrafenib) + Mekinist (trametinib) received FDAapproval for pediatric patients with low-grade glioma (pLGG) with a BRAF V600E mutation, the most … Continue Reading
Premium
Lack of Clarity Continues Pushing Affimed Lower
Insights - Affimed announced a rather disappointing update yesterday. There was not much clarity shared and it seemed like AFM24 was seeing more data delays. The main … Continue Reading
Premium
Karuna Latest Phase 3 Data Strengthens Upcoming NDA
Insights - Yesterday Karuna (KRTX) reported data on the third positive registrational trial, announcing that the trial met its primary endpoint. With three positive registrational trials reported … Continue Reading
Premium
aTyr (LIFE) Financing Makes It Late 2023 Story
Insights - aTyr (LIFE) announced a financing yesterday which diluted the company by approximately 45%. LIFE offered 22.225M shares of stock at a price of $2.25 to raise … Continue Reading
Premium